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Zusammenfassung
Bei Frauen mit Östrogenrezeptor- und ErbB2 (HER2)- 
positivem Mammakarzinom wird ein Circulus vitiosus 
zwischen den östrogenrezeptorvermittelten Wirkungen 
und dem Wachstumsfaktor-Netzwerk in Gang gesetzt, 
der in einer gesteigerten Zellproliferation und endokriner 
Resistenz resultiert. Daher ist eine gleichzeitig gegen 
ErbB1 und ErbB2 gerichtete Therapie mit Lapatinib ein 
attraktiver Ansatz, um die Wirksamkeit einer antihormo-
nellen Therapie zu steigern. Wie die Daten der EGF30008-
Studie zeigten, lassen sich mit der kombinierten Gabe 
von Letrozol und Lapatinib bei Patientinnen mit metasta-
siertem Mammakarzinom und Östrogenrezeptor/ErbB2-
Coexpression das progressionsfreie Überleben sowie 
der klinische Nutzen signifikant steigern. Daher sollte 
diese Kombination für Frauen, die sich nicht in einer akut 
lebensbedrohlichen Situation befinden, als Therapie der 
Wahl berücksichtigt werden.
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Summary
In women with estrogen receptor(ER)- and ErbB2 (HER2)-
positive breast cancer, a vicious cycle is established 
 between ER mechanisms of action and the growth factor 
receptor network, leading to enhanced cell proliferation 
and endocrine resistance. As such, co-targeting ErbB1 
and ErbB2 with lapatinib in combination with hormonal 
therapy is an attractive approach to enhance the efficacy 
of either tamoxifen or estrogen deprivation. As demon-
strated in the EGF30008 trial, a combined targeted strat-
egy with letrozole and lapatinib significantly increased 
progression-free survival and clinical benefit rates in 
 patients with metastatic breast cancer that co-expresses 
ER and ErbB2. Therefore, women who are not in an 
acutely life-threatening situation should be considered 
for upfront treatment with hormonal therapy (e.g. aro-
matase inhibitors) in combination with an anti-ErbB2 
therapy.
Introduction
Co-expression of ErbB2 (HER2) and hormone receptors 
(HR) is a rather uncommon histopathological dualism: ap-
proximately half of ErbB2-positive breast cancers also express 
HR [1], accounting therefore for 10–15% of all breast cancer 
patients. It is generally accepted that women with HR-posi-
tive metastatic breast cancer should be treated with hormonal 
therapy as an initial treatment [2, 3]. However, in the ErbB2-
positive patient population, early resistance is a significant 
issue with these endocrine agents [4]. Therefore, HR-positive 
tumors overexpressing ErbB2 still represent an important 
clinical problem and a major cause of treatment failure and 
mortality.
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inib. Furthermore, the addition of lapatinib significantly en-
hanced the sensitivity to tamoxifen. 
Clinical Evidence
Based on this preclinical evidence, the question of combined 
therapy has been addressed by the randomized, double-blind, 
placebo-controlled, multicenter phase III EGF30008 trial 
evaluating the effect of adding lapatinib to the AI letrozole as 
first-line treatment [11]. A total of 1,286 patients with ER-
positive metastatic disease were randomly assigned to receive 
daily letrozole (2.5 mg orally) plus lapatinib (1,500 mg orally; 
n = 642) or letrozole plus placebo (n = 644); of these, 17% of 
patients in each arm had tumors centrally confirmed in a com-
mercial laboratory as ErbB2-positive (n = 111 and n = 108, 
respectively). Baseline patient and disease characteristics 
were well balanced between treatment arms for both the 
ErbB2-positive (n = 219) and intention-to-treat HR-positive 
populations. As seen after a median follow-up time of 1.8 
years, the addition of lapatinib to letrozole significantly in-
creased the median progression-free survival (PFS) for HR/
ErbB2-positive women (n = 219) from 3.0 months (letrozole-
placebo) to 8.2 months, representing a statistically significant 
29% reduction in the risk of disease progression (hazard ratio 
(HR) = 0.71; 95% confidence interval (CI) 0.53–0.96; p = 
0.019) (fig. 1). Consistent with these findings, the overall re-
sponse rate (ORR) in the ErbB2-positive population was 
significantly improved from 15 to 28% for patients treated 
with letrozole-lapatinib (odds ratio (OR) = 0.4; 95% CI 0.2–
0.9; p = 0.021). Including patients with stable disease for ≥ 6 
months, the clinical benefit rate (CBR) was likewise 
significantly improved (29 to 48%; OR = 0.4; 95% CI 0.2–0.8; 
p = 0.003). With less than 50% of overall survival (OS) events 
yet recorded, the median OS in the ErbB2-positive popula-
tion was 32.3 months in the letrozole-placebo arm compared 
ErbB2/ER Pathway Crosstalk and Endocrine Resistance
Cumulative data from studies of estrogen receptor (ER) bio-
logy have identified a significant bidirectional crosstalk be-
tween the ER and growth factor-signaling networks, espe-
cially the ErbB2 signaling pathway. Estrogen has 2 known 
functional activities in breast cancer cells: in the classic ge-
nomic pathway, the hormone activates nuclear ERs, which 
leads to receptor phosphorylation, dimerization, and recruit-
ment of co-activator proteins to the estrogen-bound receptor 
complex [1, 4]. In addition, there is also an activation of ERs 
located outside the nucleus in the cytoplasm and non-nuclear 
subcellular fractions. This so-called rapid non-genomic activ-
ity leads to phosphorylation, and as a result, activation of sur-
face tyrosine kinase receptors such as the insulin-like growth 
factor I receptor (IGF-IR) as well as the ErbB2 receptor. 
This seems to be the site where the crosstalk between ER 
and growth factor receptors occurs. The molecular crosstalk 
between those two receptor systems is continuous and bidi-
rectional, and the two systems are able to activate each other 
[1, 4]. 
Estrogen-deprivation therapies such as aromatase inhibi-
tors (AIs) abolish genomic and non-genomic activities of ER 
and, therefore, could terminate the crosstalk generated in the 
presence of estrogen or tamoxifen in ErbB2-positive disease 
[1, 5, 6]. Data from preclinical models, however, suggest that 
resistance to estrogen-deprivation therapies in ErbB2-overex-
pressing breast tumors might occur through at least 2 mecha-
nisms: adaptation to an estrogen hypersensitive phenotype 
and/or by ligand-independent recruitment of co-activator 
complexes to estrogen-responsive promoters [1, 7, 8].
Given the crosstalk activation, a treatment strategy of up-
front dual targeting of both receptors with concurrent endo-
crine and anti-ErbB2 therapy appeared to be a logical ap-
proach to overcome or prevent endocrine resistance in patients 
with HR/ErbB2-positive tumors. Dual inhibitors of both ErbB1 
and ErbB2 like lapatinib might be particularly suitable.
Preclinical Data of Co-Targeting ErbB1 and ErbB2 with 
Lapatinib
As shown in several preclinical studies, there is strong evi-
dence that lapatinib may be effective in restoring tamoxifen 
sensitivity in HR-positive, tamoxifen-resistant breast cancer 
models. Chu et al. [9] demonstrated that lapatinib in combina-
tion with tamoxifen effectively inhibited the growth of 
tamoxifen-resistant, ErbB2-overexpressing MCF-7 mammary 
tumor xenografts. Leary et al. [10] showed greater antiprolif-
erative effects for the combination of lapatinib with estrogen 
deprivation than either strategy alone in long-term estrogen-
deprived and tamoxifen-resistant cells derived from parental 
hormone-sensitive MCF7 cells as well as in BT474 cells, a cell 
line with ErbB2 amplification and known sensitivity to lapat-
Fig. 1. Phase III EGF30008 trial: Kaplan-Meier estimates of progression-
free survival, adapted from [11].
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therapy alone for patients with ErbB2-positive breast cancer, 
regardless of HR status [12, 13]. On the other hand, patients 
have to tolerate the toxicities from the chemotherapy combi-
nation [12, 13].
Analogue to the therapeutic algorithm for ErbB2-negative 
patients in whom endocrine-based treatment or chemother-
apy is depending on the number and site of the metastases, 
tumor growth dynamic, and life-threatening issues, the follow-
ing therapeutic algorithm seems to be feasible when choosing 
a first-line therapy for women with metastatic HR-positive tu-
mors overexpressing ErbB2 (fig. 2): combining chemotherapy 
with targeted therapy should be the first-line treatment option 
considered in patients with acute life-threatening disease. Pa-
tients who are not in an acute life-threatening situation should 
be considered for upfront treatment with hormonal therapy 
(e.g. AIs) in combination with an anti-ErbB2 therapy. As 
demonstrated in the EGF30008 trial (lapatinib + letrozole) 
[11] as well as in the TAnDEM trial (trastuzumab + anastro-
zole) [14], this is an appropriate approach to control patients 
for a significant period of time before chemotherapy (in com-
bination with a targeted therapy) is required. Trastuzumab in 
combination with an AI is approved for this indication. The 
approval for lapatinib in combination with an AI is expected 
in 2010.
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with 33.3 months in the combination arm (HR = 0.74; 95% CI 
0.5–1.1; p = 0.113). Grade 3 or 4 adverse events were more 
common in the lapatinib-letrozole arm versus the letrozole-
placebo group (diarrhea 10 vs. 1%; rash 1 vs. 0%), but they 
were manageable. As the authors concluded, the EGF30008 
trial demonstrated that a combined targeted strategy with 
letrozole and lapatinib significantly enhances PFS and CBR in 
patients with metastatic breast cancer that co-expresses HR 
and ErbB2.
Anti-ErbB2 Therapy Combined with Endocrine Therapy 
or Chemotherapy?
The combination of trastuzumab and chemotherapy offers a 
significant survival advantage when compared with chemo-
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Postmenopausal woman with ErbB2+ + HR+ metastatic breast cancer




Present or expected life-threatening 
situation
Patient’s wish, compliance, tolerability
Targeted therapy + endocrine 
therapy
Targeted therapy + chemotherapy
 
Fig. 2. Proposed therapeutic algorithm for the first-line therapy of women 
with HR/ErbB2-positive postmenopausal metastatic breast cancer.
